SCHEDULE: Vanguard Group Discloses 9.55% Stake in Core Laboratories

The Vanguard Group has filed an amended Schedule 13G, reporting a 9.55% beneficial ownership stake in Core Laboratories Inc. as of June 30, 2025.

Summary

• The Vanguard Group, an investment adviser, reported beneficial ownership of 4,479,090 shares of Core Laboratories Inc. common stock.
• This ownership represents 9.55% of Core Laboratories Inc.'s outstanding common stock.
• Vanguard holds sole dispositive power over 4,403,371 shares and shared dispositive power over 75,719 shares.
• Vanguard holds sole voting power over 0 shares and shared voting power over 29,689 shares.
• This filing is an Amendment No. 2 to a Schedule 13G, updating a previously reported ownership position.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. A Schedule 13G filing is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the company's performance or prospects. It simply updates an institutional investor's stake.

Future Outlook

NA

Industry Context

This filing reflects a passive investment by a major institutional asset manager, The Vanguard Group, in Core Laboratories Inc., a company operating in the oilfield services sector. Such filings are common for large index fund providers and typically do not indicate a strategic shift or activist intent, but rather a portfolio allocation based on market indices or investment mandates.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which can offer some stability or liquidity in the stock.

Key Dates

Keywords

Core Laboratories Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Investment Adviser, Oilfield Services